Pfiz­er, Mer­ck KGaA throw in the tow­el on an­oth­er Baven­cio PhI­II as once bright hopes shriv­el fast

Pfiz­er and Mer­ck KGaA have hit the tri­fec­ta for PD-L1 fail­ure in ovar­i­an can­cer.

The two part­ners said late to­day that they are shut­ter­ing the Phase III JAVELIN Ovar­i­an PARP 100 study, their third straight fail in the ovar­i­an can­cer sec­tor in re­cent months. The de­ci­sion to close the tri­al, they added, was due to its ear­li­er set­backs as well as the ap­proval of As­traZeneca’s dom­i­nant PARP Lyn­parza in front­line cas­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.